Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Xcelience® Celebrates 25% Growth in 2013

Published: Monday, September 23, 2013
Last Updated: Sunday, September 22, 2013
Bookmark and Share
Company adds team members.

Xcelience has announced the completion of a milestone 25 percent increase in staff since September of 2012, growing from 85 team members then to 113.

“We’re going through a period of robust growth,” says Derek Hennecke, CEO and President. “We’ve added team members to Formulation, Preformulation and Analytical, as well as growing our new Clinical Supply Services (CSS) division. We’re also exploring new growth in commercial development with three projects on track to produce registration batches next year.”

“Most of our new employees were recruited from a strong pool of candidates here in Tampa, but we also bring talent from New Jersey, Connecticut and other states,” Hennecke says.

Hennecke continued, “The 28 new team members we’ve added in the last year have brought fresh ideas and new efficiencies to the business. As CEO I’ve learned that the best thing I can do is hire top talent and then get out of their way.”

Many of the new employees work in the company’s CSS facility located on Grace Street in Tampa, which celebrated the grand opening with a ribbon-cutting ceremony in September 2012.

“CSS has now produced well over one hundred batches and introduced a new blister and bottling line in January of this year,” says Hennecke.

“I can’t tell you how exciting it has been to show clients and potential clients our CSS capabilities and services,” says Clinical Packaging Manager, Damian Gant. “We are the only CDMO specifically targeting the clinical supplies market with a small-scale flexible service. Other companies have tried to scale down large production facilities to produce for this market, but scaling down is a bit like driving an RV to work. A large company can do the job, but it’s expensive, inflexible, inefficient, and frankly, not cut out for the job.”

“Xcelience is the only American CDMO under $2 billion in revenue that has created an entire division devoted specifically to clinical trial clients with their small runs and highly flexible production and distribution needs,” Gant adds. “The growth potential within this market is tremendous.”

Xcelience’s Formulation and Manufacturing divisions also celebrated a landmark this year, with the production of Xcelience’s four millionth Xcelodose capsule. This accomplishment cements the company’s position as an industry leader in the expertise of precision API micro-dosing.

Xcelience was the first CDMO to introduce the Xcelodose into the United States in 2005 and now operates five machines, most of which can produce upwards of 66,000 capsules per month.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Xcelience to Expand Headquarter Operations in Tampa
International pharmaceutical development and manufacturing company will create 100 new jobs, capital investment of more than $9 million.
Friday, March 20, 2015
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!